三种组织转谷氨酰胺酶IgA检测方法监测乳糜泻患者无麸质饮食反应的结果差异
该回顾性观察研究纳入44例成人和17例儿童乳糜泻患者,用三种tTG-IgA检测方法(一种FEIA和两种CLIA)监测无麸质饮食后的抗体变化,并以i-FABP作为肠上皮损伤的替代标志物。结果显示CLIA法抗体正常化较FEIA延迟(p<0.001),在无麸质饮食至少6个月且i-FABP升高的样本中,FEIA阳性率为40%,两种CLIA分别为85%和90%。结论认为tTG-IgA正常化取决于所用检测方法,CLIA对识别治疗反应不佳更敏感。
要点
- CLIA法tTG-IgA正常化较FEIA延迟,差异有统计学意义(p<0.001)。
- 无麸质饮食≥6个月且i-FABP升高时,FEIA阳性率40%,两种CLIA为85%和90%。
- 监测乳糜泻无麸质饮食反应时,tTG-IgA结果解读需考虑检测方法差异。
核心结论
- 无麸质饮食患者tTG-IgA正常化取决于所用检测方法。
- 两种CLIA在识别i-FABP升高的亚 optimal 治疗反应时较FEIA更敏感(按厂家推荐诊断cut-off)。
研究设计与样本
- 回顾性观察研究,纳入44例成人及17例儿童乳糜泻患者的诊断样本。
- 多数患者有引入无麸质饮食后的两份随访样本。
- 所有样本用一种FEIA和两种CLIA检测tTG-IgA,并检测i-FABP作为肠上皮损伤替代标志物。
主要发现
- 使用CLIA法时抗体水平正常化较FEIA延迟(p<0.001)。
- 无麸质饮食至少6个月后采集且i-FABP升高的样本中,FEIA阳性率40%,两种CLIA阳性率分别为85%和90%。
关键数值与推荐
- CLIA与FEIA正常化延迟比较的P值<0.001。
- 无麸质饮食≥6个月且i-FABP升高样本中,FEIA阳性率40%,两种CLIA阳性率85%和90%。
临床怎么用
- 监测乳糜泻患者无麸质饮食反应时,应知晓tTG-IgA检测方法间的差异。
- CLIA法可能更敏感地发现i-FABP提示的肠上皮损伤持续存在的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tissue transglutaminase (tTG) IgA antibodies are a hallmark for celiac disease (CD). In CD patients on gluten free diet (GFD) these antibodies are transient. Few studies are available comparing the tTG-IgA assay characteristics for monitoring response to GFD. Since discrepant results were reported in patients on GFD after switching tTG-IgA assays, we conducted a retrospective observational study to monitor GFD response using three different tTG-IgA assays. METHODS: Diagnostic samples from 44 adults and 17 children with CD were included. Of most patients two follow-up samples after introduction of GFD were available. In all samples tTG-IgA were assessed using one fluorochrome-enzyme immuno-assay (FEIA) and two chemiluminescence immuno-assays (CLIA) and intestinal fatty acid binding protein (i-FABP) as surrogate marker for intestinal epithelial damage was measured. RESULTS: Using CLIA assays, normalization of antibody levels was delayed compared to FEIA (p<0.001). Of all samples taken after at least 6 months on GFD with elevated i-FABP indicating intestinal epithelial damage, 40 % had positive tTG-IgA according to the FEIA, 85 and 90 % according to the two CLIA. CONCLUSIONS: Normalization of tTG-IgA in patients on GFD depends on the assay used. Both CLIA appear to be more sensitive in detecting suboptimal treatment response in CD-indicated by elevated i-FABP - when applying the manufacturer's recommended cut-off for the diagnosis of CD.
引用
- Mulder AHL, Castelijn DAR, van der Pol P, et al. Monitoring patients with celiac disease on gluten free diet: different outcomes comparing three tissue transglutaminase IgA assays. Clin Chem Lab Med. 2023. PMID: 37943101. doi:10.1515/cclm-2023-1076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。